PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes

Background: Pituitary tumor transforming gene (pttg) is a novel oncogene that is expressed at higher level in most of the tumors analyzed to date compared to normal tissues. Nevertheless, its expression in prolactinomas and its relation with the pituitary dopamine receptor 2 (D2R) are not well defin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cristina, Silvia Carolina, Díaz Torga, Graciela S., Goya, Rodolfo Gustavo, Kakar, Sham S., Pérez Millán, María I., Passos, Vanessa Q., Giannella Neto, Daniel, Bronstein, Marcello D., Becú de Villalobos, Damasia
Formato: Articulo
Lenguaje:Inglés
Publicado: 2007
Materias:
Ciencias Médicas
estrogen
messenger RNA
oncoprotein
prolactin
carcinogenesis
dopaminergic system
hypophysis
prognosis
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/35110
http://www.molecular-cancer.com/content/pdf/1476-4598-6-4.pdf
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-35110
record_format dspace
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
estrogen
messenger RNA
oncoprotein
prolactin
carcinogenesis
dopaminergic system
hypophysis
prognosis
spellingShingle Ciencias Médicas
estrogen
messenger RNA
oncoprotein
prolactin
carcinogenesis
dopaminergic system
hypophysis
prognosis
Cristina, Silvia Carolina
Díaz Torga, Graciela S.
Goya, Rodolfo Gustavo
Kakar, Sham S.
Pérez Millán, María I.
Passos, Vanessa Q.
Giannella Neto, Daniel
Bronstein, Marcello D.
Becú de Villalobos, Damasia
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
topic_facet Ciencias Médicas
estrogen
messenger RNA
oncoprotein
prolactin
carcinogenesis
dopaminergic system
hypophysis
prognosis
description Background: Pituitary tumor transforming gene (pttg) is a novel oncogene that is expressed at higher level in most of the tumors analyzed to date compared to normal tissues. Nevertheless, its expression in prolactinomas and its relation with the pituitary dopamine receptor 2 (D2R) are not well defined. We sought to determine the pituitary level of pttg in three different experimental models of prolactinomas with altered dopaminergic control of the pituitary: the dopaminergic D2R knockout female mouse, the estrogen-treated rat, and the senescent female rat. These three models shared the characteristics of increased pituitary weight, hyperprolactinemia, lactotrope hyperplasia and reduced or absent dopaminergic action at the pituitary level. We also studied samples from human macroprolactinomas, which were characterized as responsive or resistant to dopamine agonist therapy. Results: When compared to female wild-type mice, pituitaries from female D2R knockout mice had decreased PTTG concentration, while no difference in pttg mRNA level was found. In senescent rats no difference in pituitary PTTG protein expression was found when compared to young rats. But, in young female rats treated with a synthetic estrogen (Diethylstylbestrol, 20 mg) PTTG protein expression was enhanced (P = 0.029). Therefore, in the three experimental models of prolactinomas, pituitary size was increased and there was hyperprolactinemia, but PTTG levels followed different patterns. Patients with macroprolactinomas were divided in those in which dopaminergic therapy normalized or failed to normalize prolactin levels (responsive and resistant, respectively). When pituitary pttg mRNA level was analyzed in these macroprolactinomas, no differences were found. We next analyzed estrogen action at the pituitary by measuring pituitary estrogen receptor α levels. The D2R knockout female mice have low estrogen levels and in accordance, pituitary estrogen receptors were increased (P = 0.047). On the other hand, in senescent rats estrogen levels were slightly though not significantly higher, and estrogen receptors were similar between groups. The estrogen-treated rats had high pharmacological levels of the synthetic estrogen, and estrogen receptors were markedly lower than in controls (P < 0.0001). Finally, in patients with dopamine resistant or responsive prolactinomas no significant differences in estrogen receptor α levels were found. Therefore, pituitary PTTG was increased only if estrogen action was increased, which correlated with a decrease in pituitary estrogen receptor level. Conclusion: We conclude that PTTG does not correlate with prolactin levels or tumor size in animal models of prolactinoma, and its pituitary content is not related to a decrease in dopaminergic control of the lactotrope, but may be influenced by estrogen action at the pituitary level. Therefore it is increased only in prolactinomas generated by estrogen treatment, and not in prolactinomas arising from deficient dopamine control, or in dopamine resistant compared with dopamine responsive human prolactinomas. These results are important in the search for reliable prognostic indicators for patients with pituitary adenomas which will make tumor-specific therapy possible, and help to elucidate the poorly understood phenomenon of pituitary tumorigenesis.
format Articulo
Articulo
author Cristina, Silvia Carolina
Díaz Torga, Graciela S.
Goya, Rodolfo Gustavo
Kakar, Sham S.
Pérez Millán, María I.
Passos, Vanessa Q.
Giannella Neto, Daniel
Bronstein, Marcello D.
Becú de Villalobos, Damasia
author_facet Cristina, Silvia Carolina
Díaz Torga, Graciela S.
Goya, Rodolfo Gustavo
Kakar, Sham S.
Pérez Millán, María I.
Passos, Vanessa Q.
Giannella Neto, Daniel
Bronstein, Marcello D.
Becú de Villalobos, Damasia
author_sort Cristina, Silvia Carolina
title PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
title_short PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
title_full PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
title_fullStr PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
title_full_unstemmed PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
title_sort pttg expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
publishDate 2007
url http://sedici.unlp.edu.ar/handle/10915/35110
http://www.molecular-cancer.com/content/pdf/1476-4598-6-4.pdf
work_keys_str_mv AT cristinasilviacarolina pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
AT diaztorgagracielas pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
AT goyarodolfogustavo pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
AT kakarshams pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
AT perezmillanmariai pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
AT passosvanessaq pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
AT giannellanetodaniel pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
AT bronsteinmarcellod pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
AT becudevillalobosdamasia pttgexpressionindifferentexperimentalandhumanprolactinomasinrelationtodopaminergiccontroloflactotropes
bdutipo_str Repositorios
_version_ 1764820470838853635

Ejemplares similares